Company MORPHOSYS Swiss Exchange
Equities
OXMOR
DE0006632003
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
67.52 EUR | 0.00% | 0.00% | 0.00% |
05-06 | MORPHOSYS : UBS reiterates its Neutral rating | ZD |
04-30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
Business Summary
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Cancer Medicines
100.0
%
| 278 | 100.0 % | 238 | 100.0 % | -14.37% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
88.8
%
| 0 | 0.0 % | 211 | 88.8 % | - |
Europe (excluding Germany)
11.2
%
| - | - | 27 | 11.2 % | - |
Asia
0.0
%
| - | - | 0 | 0.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
Tim Demuth
CTO | Chief Tech/Sci/R&D Officer | 50 | 22-09-30 |
Julia Neugebauer
IRC | Investor Relations Contact | - | 06-08-31 |
Daniel Palmacci
PRN | Corporate Officer/Principal | - | 20-06-30 |
Ann Merchant
PRN | Corporate Officer/Principal | 59 | 17-12-31 |
Ralf Ostendorp
PRN | Corporate Officer/Principal | - | 98-12-31 |
Corporate Officer/Principal | - | 94-04-30 | |
Klaus de Wall
AUD | Comptroller/Controller/Auditor | - | 05-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
Andrew Cheng
BRD | Director/Board Member | 57 | 22-05-17 |
Krisja Vermeylen
BRD | Director/Board Member | 62 | 16-12-31 |
Sharon Curran
BRD | Director/Board Member | 56 | 19-05-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,716,423 | 31,830,703 ( 84.39 %) | 53,685 ( 0.1423 %) | 84.39 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+49.39% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- MOR Stock
- OXMOR Stock
- Company MORPHOSYS